Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
AMPH · Nasdaq · United States · Pharmaceutical Preparations
In shortAmphastar Pharmaceuticals, Inc. is profitable, generates cash and carries moderate debt, with revenue stable (−1.7% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 19.5% | 82/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 13.6% | 75/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 12.9% | 64/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 7.9% | 53/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.02× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.79× | 67/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.97× | 58/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.51× | 38/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.82 | 95/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 16.8% | 87/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.24× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 12.0% | 67/100 |
| Operating margin volatility | 6.1% | 54/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 13.0% | 89/100 |
|---|---|---|
| EPS growth, 3-year average | 5.3% | 51/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 438 | 499 | 644 | 732 | 720 |
| Cost of revenue | 238 | 250 | 293 | 358 | 364 |
| Gross profit | 200 | 249 | 351 | 374 | 356 |
| Research & development | 61 | 75 | 74 | 74 | 86 |
| Operating income | 70 | 107 | 197 | 205 | 140 |
| Interest expense | 0.9 | 1.8 | 27 | 30 | 25 |
| Pre-tax income | 84 | 116 | 171 | 190 | 124 |
| Income tax | 21 | 23 | 32 | 30 | 26 |
| Net income | 62 | 91 | 138 | 160 | 98 |
| Diluted EPS | $1.25 | $1.74 | $2.60 | $3.06 | $2.03 |
| Diluted shares (millions) | 50 | 52 | 53 | 52 | 48 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.82 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026